Edgardo Reyes Ayala, MD
Internal Medicine · Coral Gables, FLNPI 1639127525
Payments from drug & device makers
Across 454 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Johnson & Johnson$962
- Amgen$783
- AbbVie$666
- GSK$557
- plus $3K from 25 others
What the payments were for
- Food & beverage$9,120100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 104 | $1,612 |
| AstraZeneca | 47 | $1,152 |
| Johnson & Johnson(2 entities) | 37 | $962 |
| Amgen | 53 | $783 |
| AbbVie(2 entities) | 42 | $666 |
| GSK | 30 | $557 |
| Amarin Pharma, Inc. | 22 | $528 |
| Bayer | 11 | $340 |
| Boehringer Ingelheim | 9 | $300 |
| Radius Health, Inc. | 9 | $285 |
| Lilly USA, LLC | 18 | $276 |
| Novartis | 14 | $265 |
| Abbott | 11 | $248 |
| Impulse Dynamics (USA) Inc. | 2 | $226 |
| Pfizer | 10 | $201 |
| E.r. Squibb & Sons, L.L.C. | 9 | $181 |
| Merck | 5 | $158 |
| Dexcom, Inc. | 3 | $55 |
| Idorsia Pharmaceuticals US Inc | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Inspire Medical Systems, Inc. | 1 | $48 |
| Mylan Specialty L.p. | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| CSL Behring | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,152 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $87,466 |
| EliquisApixaban | 64 | $69,488 |
| MounjaroTirzepatide | 50 | $55,806 |
| JanuviaSitagliptin Phosphate | 49 | $54,659 |
| ProliaDenosumab | 17 | $29,149 |
| FarxigaDapagliflozin Propanediol | 26 | $24,654 |
| RybelsusSemaglutide | 15 | $19,270 |
| XareltoRivaroxaban | 15 | $18,677 |
| EntrestoSacubitril/Valsartan | 14 | $17,230 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,458 |
| VascepaIcosapent Ethyl | 12 | $12,369 |
| LivaloPitavastatin Calcium | 11 | $10,752 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $10,590 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $10,489 |
| Omega-3 Acid Ethyl Esters | 95 | $9,337 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,612 | $106,73686 claims |
| PfizerEliquis | $201 | $69,48864 claims |
| Lilly USA, LLCMounjaro | $276 | $55,80650 claims |
| MerckJanuvia | $158 | $54,65949 claims |
| AstraZenecaFarxiga, Symbicort | $1,152 | $29,28238 claims |
| AmgenProlia | $783 | $29,14917 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $557 | $25,04842 claims |
| Johnson & JohnsonXarelto | $962 | $18,67715 claims |
| NovartisEntresto | $265 | $17,23014 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $16 | $10,75211 claims |
| AbbVieSynthroid | $666 | $3,44728 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Coral Gables
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Jeffrey RosenCoral Gables$17M
- Carlos IglesiasCoral Gables$6.6M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.